Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sage Therapeutics, Inc.    SAGE

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sage Therapeutics, Inc.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Number of employees : 675 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Novel Medicines90.27100%6.87100% -92.39%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States90.27100%6.87100% -92.39%
Managers
NameAgeSinceTitle
Jeffrey Jonas662013President, Chief Executive Officer & Director
Kevin Starr562013Chairman
Michael Cloonan482020Chief Operating Officer
Kimi E. Iguchi56-Chief Financial Officer & Treasurer
Albert J. Robichaud, Dr.582011Chief Scientific Officer
James Doherty, Dr.-2017Chief Research Officer
Stephen J. Kanes, Dr.542013Chief Medical Officer
Steven Marc Paul, Dr.682014Independent Director
James M. Frates512014Independent Director
Michael F. Cola592014Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 52,047,696 51,071,858 98.1% 3,033 0.0% 98.1%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 7,732,540 14.9%
The Vanguard Group, Inc. 4,658,897 8.96%
T. Rowe Price Associates, Inc. (Investment Management) 2,819,052 5.42%
D. E. Shaw & Co. LP 2,122,156 4.08%
Great Point Partners LLC 2,102,368 4.05%
Citadel Advisors LLC 1,763,613 3.39%
Invesco Advisers, Inc. 1,705,278 3.28%
SSgA Funds Management, Inc. 1,488,399 2.86%
Janus Capital Management LLC 1,459,676 2.81%
OppenheimerFunds, Inc. 1,443,145 2.78%
Company contact information
SAGE Therapeutics, Inc.
215 1st Street
Cambridge, MA 02142

Phone : +1.617.299.8380
Fax : +1.617.299.8379
Web : http://www.sagerx.com
Sector Biotechnology & Medical Research - NEC